Carbidopa ester transdermal

Drug Profile

Carbidopa ester transdermal

Alternative Names: Carbidopa prodrug transdermal; ND 0611

Latest Information Update: 06 Mar 2013

Price : $50

At a glance

  • Originator NeuroDerm
  • Class Antiparkinsonians; Catecholamines; Hydrazines
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 11 Dec 2015 Biomarkers information updated
  • 04 Mar 2013 Carbidopa ester transdermal is still in clinical development for Parkinson's disease in Israel
  • 14 Nov 2011 Parmacokinetics data from a phase I/II trial in Parkinson's disease released by NeuroDerm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top